PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?

Inclusion Criteria: * Written informed consent. * Adult patients with histopathologically\* confirmed breast carcinoma who have received surgery for their breast cancer; planned to receive 6 cycles of EC 90 (total planned dose 540mg/m2 epirubicin) or FEC 75 (total planned dose 450mg/m2 epirubicin) adjuvant chemotherapy regimen. Patients with HER2+ breast cancer are eligible for inclusion. OR * Adult patients with histopathologically confirmed non-Hodgkin lymphoma (NHL), planned to receive 6 cycles of R-CHOP or CHOP (total planned dose 300mg/m2 doxorubicin) chemotherapy\*\* * Patients with HER2+ breast cancer are eligible for inclusion. \*\* Patients who will receive an alternative anti-CD20 monoclonal antibody are eligible (for example O-CHOP), as long as the total planned doxorubicin dose is ≥300mg/m2 over 6 cycles Exclusion Criteria: * Positive baseline cardiac troponin T (≥14ng/L); * known contraindication to ACE inhibitor e.g. renal artery stenosis, severe aortic stenosis; * are taking, or have a previous intolerance to ACEI (e.g. angioedema); * patient already taking other agents acting on the renin-angiotensin-aldosterone system e.g. Aliskiren, angiotensin receptor blockers (ARBs), Entresto (sacubitril/valsartan), spironolactone, eplerenone; * LVEF \<50%\*; * estimated GFR \< 30 mL/min/1.73m2 at baseline; * hyperkalaemia defined as serum potassium ≥5.5mmol/L; * symptomatic hypotension, or Systolic Blood Pressure \<100mmHg; * poorly-controlled hypertension (Blood…